论文部分内容阅读
方法:进行了一项用螺内酯25～50mg治疗难治性高血压的开放性观察研究。对133例已接受一种血管紧张素阻断剂联合其他治疗方法的患者推荐使用此药。结果:在这些患者中,3例患者失访,11例不能耐受螺内酯。因此,最终得到了119例患者的预后资料。加用螺内酯(中位剂量25ms)导致收缩压降低21.7±24.0mmHg(P<0.001),舒张压降低8.5±14.9mmHg(P<0.001)。
METHODS: An open-label study was conducted on the treatment of refractory hypertension with spironolactone 25-50 mg. This medicine is recommended for 133 patients who have received an angiotensin blocker in combination with other therapies. RESULTS: Of these patients, 3 were lost to follow-up and 11 were unable to tolerate spironolactone. Therefore, the prognosis of 119 patients was finally obtained. Treatment with spironolactone (median dose of 25 ms) resulted in a 21.7 ± 24.0 mmHg reduction in systolic blood pressure (P <0.001) and an 8.5 ± 14.9 mmHg diastolic reduction (P <0.001).